Zaven S Khachaturian,
Deborah Barnes,
Richard Einstein,
Sterling Johnson,
Virginia Lee, Allen Roses,
Mark A Sager,
William R Shankle,
Peter J Snyder,
Ronald C Petersen, [......],
Creighton Phelps,
Eric Reiman,
Marwan Sabbagh,
Mary Sano,
Lon S Schneider,
Eric Siemers,
Pierre Tariot,
Jacques Touchon,
Bruno Vellas,
Lisa J Bain
[show abstract]
[hide abstract]
ABSTRACT: Among the major impediments to the design of clinical trials for the prevention of Alzheimer's disease (AD), the most critical is the lack of validated biomarkers, assessment tools, and algorithms that would facilitate identification of asymptomatic individuals with elevated risk who might be recruited as study volunteers. Thus, the Leon Thal Symposium 2009 (LTS'09), on October 27-28, 2009 in Las Vegas, Nevada, was convened to explore strategies to surmount the barriers in designing a multisite, comparative study to evaluate and validate various approaches for detecting and selecting asymptomatic people at risk for cognitive disorders/dementia. The deliberations of LTS'09 included presentations and reviews of different approaches (algorithms, biomarkers, or measures) for identifying asymptomatic individuals at elevated risk for AD who would be candidates for longitudinal or prevention studies. The key nested recommendations of LTS'09 included: (1) establishment of a National Database for Longitudinal Studies as a shared research core resource; (2) launch of a large collaborative study that will compare multiple screening approaches and biomarkers to determine the best method for identifying asymptomatic people at risk for AD; (3) initiation of a Global Database that extends the concept of the National Database for Longitudinal Studies for longitudinal studies beyond the United States; and (4) development of an educational campaign that will address public misconceptions about AD and promote healthy brain aging.
Alzheimer's & dementia: the journal of the Alzheimer's Association 03/2010; 6(2):89-97. · 5.90 Impact Factor
